Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.40 |
| ▸ | AURKA | O14965 | 6/20 | 0.39 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15550428 | 0.87 | JAK3 (0.51) | JAK3JAK2PTK2LCKBTK | |
| SCHEMBL15007575 | 0.79 | SYK (0.46) | SYKAURKAJAK3JAK2PTK2 | |
| SCHEMBL15550771 | 0.78 | SYK (0.49) | SYKAURKAJAK3JAK2PTK2 | |
| SCHEMBL15552071 | 0.78 | SYK (0.60) | SYKAURKAJAK3JAK2LCK | |
| SCHEMBL2217499 | 0.76 | CCND3 (0.51) | SYKAURKAJAK3JAK2PTK2 | |
| SCHEMBL15552431 | 0.73 | SYK (0.51) | SYKJAK2 | |
| SCHEMBL4830899 | 0.73 | SYK (0.41) | SYKAURKA | |
| SCHEMBL30850442 | 0.73 | SYK (0.43) | SYKAURKABTK | |
| SCHEMBL1068037 | 0.72 | SYK (0.52) | SYKAURKABTK | |
| SCHEMBL23459446 | 0.72 | JAK3 (0.50) | SYKJAK3JAK2PTK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | SYK 65/4885AURKA 1439/4885JAK3 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.